新西兰药房建议,新诊断的系统性塑性大细胞淋巴瘤将brentuximab vedotin第一线用于新诊断的系统性塑性大细胞淋巴瘤,每年受益人数多达2 500人。 New Zealand's Pharmac proposes first-line use of brentuximab vedotin for newly diagnosed systemic anaplastic large cell lymphoma, benefiting up to 2,500 annually.

Pharmac建议扩大新西兰新诊断的系统性塑性大细胞淋巴瘤患者获得brentuximab vedotin的brentuximab vedotin的机会,允许将其作为一线治疗。 Pharmac is proposing to expand access to brentuximab vedotin for newly diagnosed systemic anaplastic large cell lymphoma patients in New Zealand, allowing it as a first-line treatment. 这一改变是更广泛的癌症护理升级的一部分,每年可惠及多达2 500人。 The change, part of a broader cancer care upgrade, could benefit up to 2,500 people annually. 这一行动是在药房资金增加62.94亿美元后采取的,使43个新的癌症治疗和扩大干细胞移植服务成为可能。 The move follows a $6.294 billion funding boost for Pharmac, enabling 43 new cancer treatments and expanded stem cell transplant access. 对该提案的磋商持续到2026年2月19日。 Consultation on the proposal runs until 19 February 2026.